GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Philogen SpA (STU:78Q) » Definitions » Institutional Ownership

Philogen SpA (STU:78Q) Institutional Ownership : 5.14% (As of Apr. 28, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Philogen SpA Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Philogen SpA's institutional ownership is 5.14%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Philogen SpA's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Philogen SpA's Float Percentage Of Total Shares Outstanding is 0.00%.


Philogen SpA Institutional Ownership Historical Data

The historical data trend for Philogen SpA's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Philogen SpA Institutional Ownership Chart

Philogen SpA Historical Data

The historical data trend for Philogen SpA can be seen below:

2024-05-31 2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Institutional Ownership 4.95 5.06 5.14 5.14 5.14 5.18 5.09 5.07 5.14 5.14

Philogen SpA Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Philogen SpA Business Description

Traded in Other Exchanges
Address
Piazza La Lizza No. 7, Siena, ITA, 53100
Philogen SpA is a biotechnology company. The company develops biotech products for the imaging and therapy of life-threatening diseases. The company's focus is predominantly related to oncology drug development, although the company has also brought products for the treatment of chronic inflammatory diseases to the clinic. Its pipeline products include Nidlegy; Fibromun; Darleukin; Dodekin; Dekavil and others. Geographically, the company operates in the European Union, Switzerland, and the United States of America.

Philogen SpA Headlines

No Headlines